Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.22M$3.22Mderived+1,294.8% vs Q4 2023 Net Income-$74.22M-$74.22MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$73,519,000N/M Operating Cash Flowderived-$34,204,000N/M Free Cash Flowderived-$34,423,000N/M Margins · derivedOperating margin-2281.8%+19300.9 pt vs Q4 2023
Net margin-2303.4%+18439.9 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 24, 2025 · 83 d after period end